No other candidate assays reached 90% sensitivity and specificity in the meta-analysis for either the 50% or the 1% tumor proportion score cut-off for PD-L1 IHC 22C3 pharmDx (Table 1 and Table 3). The gene discussed is CD274; the disease is neoplasm.